Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 3, 2017, Pages

  Nelson, Richard L ^a   Suda, Katie J ^a   Evans, Charlesnika T ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACITRACIN; FIDAXOMICIN; FUSIDIC ACID; METRONIDAZOLE; TEICOPLANIN; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; CLINICAL OUTCOME; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE EFFECTIVENESS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ADULT; CHEMICALLY INDUCED; COMPLICATION; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; META ANALYSIS; MICROBIOLOGY; TREATMENT OUTCOME;

ADULT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACITRACIN; CLOSTRIDIUM DIFFICILE; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; METRONIDAZOLE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TEICOPLANIN; TREATMENT OUTCOME; VANCOMYCIN;

EID: 85014323548     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004610.pub5     Document Type: Review

References (97)

1. Anonymous . Treatment of Clostridium difficile-associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group. Scandinavian Journal of Infectious Diseases 1994;26(3):309-16. 5295765
2. Boero M, Berti E, Morgando A, Verme G. Treatment of pseudomembranous colitis: a randomized controlled trial with rifaximin vs vancomycin [Terapia della colite da Clostridium difficile: risultati di uno studio randomizzato aperto rifaximina vs. vancomicina]. Microbiologia Medica 1990;5(2):74-7. 3265027
3. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infectious Diseases 2012;12(4):281-9. 5295766
4. De Lalla F, Nicolin R, Rinaldi E, Scarpellini P, Rigoli R, Manfrin V, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrobial Agents and Chemotherapy 1992;36(10):2192-6. 5295767
5. Dudley MN, McLaughlin JC, Carrington G, Frick J, Nightingale CH, Quintiliani R. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Archives of Internal Medicine 1986;146(6):1101-4. 5295768
6. Fekety R, Silva J, Kauffman C, Buggy B, Deery HG. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. American Journal of Medicine 1989;86(1):15-9. 5295769
7. Garey KW, Ghantoji SS, Shah DN, Habib M, Arora V, Jiang ZD, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy 2011;66(12):2850-5. 5295770
8. Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases 2014;59(3):345-54. 5295771
9. Keighley MR, Burdon DW, Arabi Y, Williams JA, Thompson H, Youngs D, et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. British Medical Journal 1978;2(6153):1667-9. 3265043
10. Lagrottereria D, Holmes S, Smieja M, Smaill F, Lee C. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clinical Infectious Diseases 2006;43(5):547-52. 5295772
11. Lee CH, Patino H, Stevens C, Rege S, Chesnel L, Louie T, et al. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial. Journal of Antimicrobial Chemotherapy 2016;71(10):2964-71. 5295774
12. Louie T, Miller M, Donskey C, Mullane K, Goldstein EJ. Clinical outcomes, safety and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy 2009;53(1):223-8. 3265047
13. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine 2011;364(5):422-31. 5295775
14. Louie T, Nord CE, Talbot GH, Wilcox M, Gerding DN, Buitrago M, et al. Multicenter, double-blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy 2015;59(10):6266-73. 5295776
15. Mullane K, Lee C, Bressler A, Buitrago M, Weiss K, Dabovic K, et al. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrobial Agents and Chemotherapy 2015;59(3):1435-40. 3265053
16. Musher DM, Logan N, Hamill RJ, Dupont HL, Lentnek A, Gupta A, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clinical Infectious Diseases 2006;43(4):421-7. 5295777
17. Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clinical Infectious Diseases 2009;48(4):41-6. 5295778
18. Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983;2(8358):1043-6. 5295779
19. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clinical Infectious Diseases 1996;22(5):813-8. 5295780
20. Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. Journal of Antimicrobial Chemotherapy 2004;54(1):211-6. 5295781
21. Young GP, Ward PB, Bayley N, Gordon D, Higgins G, Trapani JA, et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 1985;89(5):1038-45. 5295782
22. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clinical Infectious Diseases 2007;45(3):302-7. 5295783
23. Barker A, Duster M, Valentine S, Archbald-Pannone L, Guerrant R, Safdar N. Probiotics for Clostridium difficile infection in adults (PICO): Study protocol for a double-blind, randomized controlled trial. Contemporary Clinical Trials 2015;44:26-32. 5295785
24. Basu P, Krishnaswamy N, Shah J, Tang C. Comparison of nitazoxanide and vancomycin taper regimens as a salvage therapy for patients with recurrent mild to moderate Clostridium difficile infection (CDI). Gastroenteology 2011;140(5):s325. 5295786
25. Brumley PE, Malani AN, Kabara JJ, Pisani J, Collins CD. Effect of an antimicrobial stewardship bundle for patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy 2016;71(3):836-40. 5295788
26. Cammarota G, Masucci L, Ianiro G, Bibbo S, Dinoi G, Costamagna G, et al. Randomised clinical trial: Faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Alimentary Pharmacology and Therapeutics 2015;41(9):835-43. 5295790
27. De Bruyn G, Saleh J, Workman D, Pollak R, Elinoff V, Fraser NJ, et al. Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized phase 2 clinical trial. Vaccine 2016;34(19):2170-8. 5295792
28. Forster AJ, Daneman N, van Walraven C. Influence of antibiotics and case exposure on hospital-acquired Clostridium difficile infection independent of illness severity. Journal of Hospital Infection 2016 Oct 14 [Epub ahead of print]. [DOI: 10.1016/j.jhin.2016.10.007]5295794
29. Gerding DN, Hecht DW, Louie T, Nord CE, Talbot GH, Cornely OA, et al. Susceptibility of Clostridium difficile isolates from a phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection. Journal of Antimicrobial Chemotherapy 2016;71(1):213-9. 5295795
30. Hossam M, Elsisi G. Cost-effectiveness analysis of fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in Egypt. Value in Health 2016;19(7):A513. 5295797
31. Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Annals of Internal Medicine 1992;117(4):297-302. 5295798
32. Kaki R, Brooks A, Main C, Jayaratne P, Mertz D. Does extending Clostridium difficile treatment in patients who are receiving concomitant antibiotics reduce the rate of relapse?. Internet Journal of Infectious Diseases 2016;15(1):1-5. 5295800
33. Lee CH, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: A randomized clinical trial. JAMA 2016;315(2):142-9. 5295802
34. Lee C, Louie TJ, Weiss K, Valiquette L, Gerson M, Arnott W, et al. Fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection: Canadian outcomes. Canadian Journal of Infectious Diseases and Medical Microbiology 2016;2016:Article Number: 8048757. 5295804
35. Louie TJ, Peppe J, Watt CK, Johnson D, Mohammed R, Dow G, et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clinical Infectious Diseases 2006;43(4):411-20. 5295805
36. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. New England Journal of Medicine 2010;362(3):197-205. 5295806
37. Mattila E, Anttila VJ, Broas M, Marttila H, Poukka P, Kuusisto K, et al. A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: Efficacy and safety of a prematurely interrupted trial. Scandinavian Journal of Infectious Diseases 2008;40(9):702-8. 5295807
38. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. American Journal of Gastroenterology 2002;97(7):1769-75. 5295808
39. Mullane KM, Adachi J, Dubberke E, Alexander B, Broyde N, Sears P. Outcomes of deflect-1: A multicenter, blinded, randomized clinical trial of fidaxomicin (FDX) vs. placebo (PLC) for prophylaxis of Clostridium difficile-associated diarrhea (CDAD) in subjects undergoing hematopoietic stem cell transplantation (HSCT). Biology of Blood and Marrow Transplantation 2016;22(3 Suppl 1):S171. 5295810
40. Noren T, Wullt M, Akerlund T, Back E, Odenholt I, Burman LG. Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid. Antimicrobial Agents and Chemotherapy 2006;50(9):3028-32. 5295811
41. Numan SC, Veldkamp P, Kuijper EJ, van den Berg RJ, van Dissel JT. Clostridium difficile-associated diarrhoea: bovine anti-clostridium difficile whey protein to help aid the prevention of relapses. Gut 2007;56(6):888-9. 5295812
42. Thabit AK, Nicolau DP. Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in Clostridium difficile infection. International Journal of Antimicrobial Agents 2015;46(2):205-8. 5295814
43. Welch HK, Nagel JL, Patel TS, Gandhi TN, Chen B, De Leon J, et al. Effect of an antimicrobial stewardship intervention on outcomes for patients with Clostridium difficile infection. American Journal of Infection Control 2016;44(12):1539-43. 5295816
44. Pardi DS, Brennan R, Spinnell M, Gareca MG, Greenberg E, Tian W, et al. The efficacy and safety of rifaximin vs. vancomycin in the treatment of mild to moderate C. difficile infection: A randomized double-blind active comparator trial. Gastroenterology 2012;142(5 Suppl 1):S599. 5295817
45. Shyh G, Todorov D, Cohen H, Mukhtarzad R, Brooks S. Oral vancomycin plus intravenous metronidazole versus oral vancomycin in severe Clostridium difficile-associated diarrhea: a single center study. Pharmacotherapy 2014;34(10):259-60. 5295818
46. NCT01983683 . A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD). clinicaltrials.gov/ct2/show/NCT01983683 (accessed 7 November 2013). 5295819
47. NCT01987895 . A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD). clinicaltrials.gov/ct2/show/NCT01987895 (accessed 7 November 2013). 3265093
48. Minnesota Evidence-based Practice Center. Early diagnosis, prevention and treatment of Clostridium difficile: Update. AHRQ Publication No. 16-EHC012-EF March, 2016; Vol. #172:1-37.
49. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000;355(9209):1064-9.
50. Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 2015;313(4):398-408.
51. Baker SG, Kramer BS. The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C?. BMC Medical Research Methodology 2002;2:13.
52. Bartlett JG, Taylor NS, Chang T, Dzink J. Clinical and laboratory observations in Clostridium difficile colitis. American Journal of Clinical Nutrition 1980;33(11 Suppl):2521-6.
53. Bartlett JG. Clostridium difficile: clinical considerations. Reviews of Infectious Diseases 1990;12 Suppl 2:S243-51.
54. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. New England Journal of Medicine 2002;346(5):334-9.
55. Bauer MP, Kuijper EJ, van Dissel JT. European society of clinical microbiology and infectious diseases (ESCMID): treatment guidance for Clostridium difficile infection (CDI). Clinical Microbiology and Infection 2009;15(12):1067-79.
56. Bishara J, Wattad M, Paul M. Vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea. Clinical Infectious Diseases 2007;45(12):1646-7.
57. Bowden TA Jr, Mansberger AR Jr, Lykins LE. Pseudomembranous enterocolitis: mechanism for restoring floral homeostasis. American Surgeon 1981;47(4):178-83.
58. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for clostridium difficile infection in adults: 2010 update for the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology 2010;31(5):431-55.
59. Di X, Bai N, Zhang X, Liu B, Ni W, Wang J, et al. A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity. Brazilian Journal of Infectious Diseases 2015;19(4):339-49. [PUBMED: 26001980]
60. Drekonja DM, Butler M, MacDonald R, Bliss D, Filice GA, Rector TS, et al. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Annals of Internal Medicine 2011;155(12):839-47.
61. Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993;269(1):71-5.
62. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American Journal of Gastroenterology 1997;92(5):739-50.
63. Garattini S, Bertele V. Non-inferiority trials are unethical because they disregard patients' interests. Lancet 2007;370:1875-6.
64. George WL, Rolfe RD, Finegold SM. Clostridium difficile and its cytotoxin in feces of patients with antimicrobial agent-associated diarrhea and miscellaneous conditions. Journal of Clinical Microbiology 1982;15(6):1049-53.
65. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr. Clostridium difficile-associated diarrhea and colitis. Infection Control and Hospital Epidemiology 1995;16(8):459-77.
66. Gotzsche P. Lessons from and cautions about noninferiority and equivalence randomized trials. JAMA 2006;295(10):1172-4.
67. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
68. Johns Hopkins. Teicoplanin. www.hopkins-abxguide.org/antibiotics/antibacterial/glycopeptide/teicoplanin.html?contentInstanceId=254836 2009.
69. Health Protection Agency of the Department of Health, UK . Clostridium difficile infection: How to deal with the problem. www.gov.uk/government/uploads/system/uploads/attachment_data/file/340851/Clostridium_difficile_infection_how_to_deal_with_the_problem.pdf (accessed 26 January 2017).
70. Health Protection Agency. Deaths involving Clostridium difficile or MRSA, Wales: 2015. www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsinvolvingclostridiumdifficilewales/2015 (accessed 26 January 2017).
71. Johnson S, Gerding DN, Louie TJ, Ruiz NM, Gorbach SL. Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea. Antimicrobial Agents and Chemotherapy 2012;56(8):4043-5.
72. Karas JA, Enoch DA, Aliyu SH. A review of mortality due to Clostridium difficile infection. Journal of Infection 2010;61(1):1-8.
73. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. New England Journal of Medicine 1994;330(4):257-62.
74. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. Journal of Clinical Gastroenterology 2010;44(5):354-60.
75. Laurence J. Deaths from "dirty hospital bug" double in five years. The Independant 26 May, 2006:11.
76. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium difficile infection in the United States. New England Journal of Medicine 2015;372(9):825-34.
77. Locher HH, Caspers P, Bruyere T, Schroeder S, Pfaff P, Knezevic A, et al. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrobial Agents and Chemotherapy 2014;58(2):901-8.
78. Louie TJ. How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?. Canadian Medical Association Journal 2005;173(9):1049-50.
79. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. New England Journal of Medicine 2005;353(23):2433-41.
80. McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. American Journal of Gastroenterology 1995;90(3):439-48.
81. Miesel L, Hecht DW, Osmolski JR, Gerding D, Flattery A, Li F, et al. Kibdelomycin is a potent and selective agent against toxigenic Clostridium difficile. Antimicrobial Agents and Chemotherapy 2014;58(4):2387-92.
82. Novell MJ, Morreale CA. The relationship between inpatient fluoroquinolone use and Clostridium difficile-associated diarrhea. Annals of Pharmacotherapy 2010;44(5):826-31.
83. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. Canadian Medical Association Journal 2005;173(9):1037-42.
84. Privitera G, Scarpellini P, Ortisi G, Nicastro G, Nicolin R, de Lalla F. Prosepctive study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrobial Agents and Chemotherapy 1991;35(1):208-10.
85. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerging Infectious Diseases 2007;13(9):1417-9.
86. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, Available from www.cochrane-handbook.org, 2011.
87. Sedgwick P. Multiple hypothesis testing and Bonferroni's correction. BMJ (Clinical research ed.) 2014;349:g6284.
88. Soonawala D, Middelberg RA, Egger M, Vandenbroucke JP, Dekkers OM. Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials.. International Journal of Epidemiology 2010;39(6):1567-81.
89. Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005;128(3):764-70.
90. Steiner C, Barrett M, Sun Y. HCUP projections: Clostridium difficile hospitalizations. HCUP Projections Report 2015;02:1-12.
91. Stewart DB, Hollenbeak CS, Wilson MZ. Is colectomy for fulminant Clostridium difficile colitis life saving? A systematic review. Colorectal Disease 2013;15(7):798-804.
92. Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. Journal of Antimicrobial Chemotherapy 2003;51(6):1339-50.
93. Van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal E, De Vos W, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. New England Journal of Medicine 2013;368(5):407-15.
94. Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, Falagas ME. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. International Journal of Antimicrobial Agents 2012;40(1):1-8.
95. Bricker E, Garg R, Nelson R, Loza A, Novak T, Hansen J. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD004610.pub2]
96. Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD004610.pub3]
97. Nelson RL, Kelsey P, Leeman H, Meardon N, Patel H, Paul K, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database of Systematic Reviews 2011, Issue 9. [DOI: 10.1002/14651858.CD004610.pub4]